News - Biotechnology
Fairfax County makes push for biotechnology space
8 February 2013
Fairfax County officials are hoping to lure scientists to the west side of the Potomac with state-of-the-art labs and a new focus on biotechnology. With the looming threat of sequestration -- $1 trillion in spending cuts and the cascading effect that ...
Click on the link to read the full article at Washington Examiner (This link will open in a new window)Bolder Biotechnology, Inc.-Product Pipeline Review-2012 New Report
7 February 2013
This report is built using data and information sourced from databases, Bolder Biotechnology, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Bolder Biotechnology, Inc. and industry-specific third ...
Click on the link to read the full article at SBWire (press release) (This link will open in a new window)WVSU moves Full STEAM Ahead with biotechnology program
7 February 2013
The 3,800-square foot commercial space adjacent to Bartlett House's current facility on University Avenue in Morgantown is valued at $200,000. The 3,800-square foot commercial space adjacent to Bartlett House's current facility on University Avenue in ...
Click on the link to read the full article at State Journal (This link will open in a new window)Brazil to boost biotechnology sector
7 February 2013
President Rousseff "recommended creating a biotechnology programme to be developed by the Science and Technology and Education ministries", Minister of Science, Technology and Innovation Marco Antonio Raupp said Wednesday, Xinhua reported.
Click on the link to read the full article at Daijiworld.com (This link will open in a new window)9 Biotechnology Stocks to Sell Now
7 February 2013
Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. As of Feb. 6, 2013, 45.3% of outstanding Spectrum Pharmaceuticals shares were held short. For a full ...
Click on the link to read the full article at Investorplace.com (This link will open in a new window)4 Biotechnology Stocks to Buy Now
6 February 2013
The grades of four Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an ?A? (?strong buy?) or ?B? overall (?buy?). Keryx Biopharmaceuticals (NASDAQ:KERX) is bettering its rating of C (?hold?) from last ...
Click on the link to read the full article at Investorplace.com (This link will open in a new window)A Closer Look At The iShares NASDAQ Biotechnology Index (IBB)
5 February 2013
The back-to-back reversal candlesticks (bullish followed by bearish) created a few false breakouts in ETFs we have been monitoring. The iShares NASDAQ Biotechnology Index (NASDAQ:IBB) broke out from a tight-ranged handle last Friday but failed to ...
Click on the link to read the full article at ETF Daily News (blog) (This link will open in a new window)Long/short biotechnology hedge fund launched
5 February 2013
Long/short biotechnology hedge fund launched. by Rob Langston - 5 February, 2013. Keywords: US. EcoR1 Capital Fund set up by former Biotechnology Value Fund portfolio manager. You need to have a subscription to read the full article.
Click on the link to read the full article at HFMWeek (This link will open in a new window)Generex Biotechnology Corporation (OTC:GNBT) Cools Down After Spike
5 February 2013
Yesterday Generex Biotechnology Corporation (OTC:GNBT, GNBT message board) failed to restrain the slide it went into, following a spike last Thursday. The stock slipped another 21%, closing down in double-digits for the third day in a row, and settled ...
Click on the link to read the full article at HotStocked (This link will open in a new window)Cuba - Investing In Biotechnology To Battle Cancer
4 February 2013
Dr. Augstin Lage Davila, General Director of the Center of Molecular Immunology (CIM), said "Biotechnology is key to transforming cancer from a deadly disease into a chronic one. Our drugs make chemo and radiation therapies more effective and less toxic.
Click on the link to read the full article at Medical News Today (This link will open in a new window)
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
